NEW YORK, Aug. 21 – Genomics-based neuroscience startup Renovis has appointed Corey Goodman to the position of president, CEO, and member of the board of directors, the company said Tuesday.
Goodman, a neuroscientist at the University of California, Berkeley, and investigator with the Howard Hughes Medical Institute, co-founded Renovis in February 2000 with several other neuroscientists. He has previously served the company only in an advisory capacity, but will assume his new executive position on September 1.
Renovis’ acting president and chief operating officer, Lynne Zydowsky, who also co-founded the company, will continue to serve as COO, but will also assume the role of senior vice president, business development, on September 1.
In addition, the company created two new executive positions, naming Tito Serafini chief discovery scientist and vice president for genomic research, and Andrew Shyjan vice president, molecular biology.
Serafini, previously a neurobiologist at the University of California, Berkeley, is also a co-founder of Renovis. Shyjan has served as senior director for cancer research at Incyte Genomics and director of oncology at Millenium Pharmaceuticals.
Renovis, based in South San Francisco, Calif., studies gene expression profiles in neuronal cell types to identify drug targets associated with neuronal regeneration, pain, behavioral disorders, and psychiatric diseases. The company raised $16.4 million in venture capital last year and employs 37 people.